Overview

Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients

Status:
Completed

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

To describe the rate of discontinuation among Non-Valvular Atrial Fibrillation (NVAF) patients who were on warfarin and have switched to the Novel oral anticoagulants(NOACs).

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Anticoagulants
Apixaban
Dabigatran
Rivaroxaban
Warfarin